Hepatoma Research Received Its First Impact Factor！
On June 20, 2024, Clarivate released the 2023 edition of the Journal Citation Reports™ (JCR™). Hepatoma Research received its first impact factor of 1.7 since its inception in 2015! It is ranked in the Q3 quartile within the field of Gastroenterology & Hepatology.
Since its establishment, Hepatoma Research has upheld rigorous publishing principles, enforced strict peer review, and maintained high-quality standards, focusing on the forefront of basic research and publishing high-quality papers. In 2019, Hepatoma Research became a member of the Committee on Publication Ethics (COPE); in 2021, it was accepted for inclusion in Scopus by the Content Selection & Advisory Board (CSAB) after a rigorous evaluation; in 2023, it was included in the Emerging Sources Citation Index (ESCI); and in May 2024, it achieved a remarkable CiteScore of 3.2 for 2023. Now, in June 2024, it attains its first impact factor of 1.7.
Hereby, Prof. Guangwen Cao, Editor-in-Chief of Hepatoma Research, together with the entire editorial team, sincerely thanks the journal's Editorial Board members, authors, peer reviewers, esteemed readers, and friends who have consistently supported and cared about the journal's development.
Hepatoma Research will continue to adhere to high publishing standards, striving to deliver excellent content on liver cancer research and disseminate cutting-edge advancements.
Editor: Ada Zhong
Language Editor: Catherine Yang
Production Editor: Yan Zhang
Respectfully submitted by the Editorial Office of Hepatoma Research
